A comparative effectiveness study examined whether primary cytoreductive surgery or neoadjuvant chemotherapy produces longer survival rates in patients with high-grade serous ovarian carcinoma.

News

Adjuvant chemotherapy given during and after pelvic radiation for high-risk endometrial cancer improves failure-free, but not overall, survival at five years and may be discussed as an alternative to radiation alone.
Survival is significantly greater with cisplatin and optimal radiation compared with radiation treatment alone for women with stage IIIB squamous cell carcinoma of the uterine cervix.
A recent study found that being taller in adolescence, as well as losing and gaining weight multiple times, is associated with increased ovarian cancer risk and mortality.
The adoption of neoadjuvant chemotherapy for advanced epithelial ovarian cancer led to a significant reduction in all-cause mortality within 3 years after diagnosis.

Research in Review

A combination regimen involving standard carboplatin chemotherapy and a novel drug may improve overall survival for more than 50% of women with high-grade serous ovarian cancers, according to research published in Precision Oncology (published online May 2017; doi:10.1038/s41698-017-0008-z).

-----

Related Content

Read More

Common comorbidities such as hypertension, heart disease, and diabetes may contribute to a woman’s prognosis after being diagnosed with ovarian cancer, according to a study published in Cancer Causes Control (2017;28[5]:469-486).

-----

Related Content

Read More

Women with stage II-IV low-grade serous carcinoma of the ovary or peritoneum who received hormonal maintenance therapy after primary treatment had longer progression-free survival (PFS) compared with women who underwent routine observation after primary treatment.
-----
Related Content

Read More

Primary cytoreductive surgery (PCS) is better than neoadjuvant chemotherapy (NACT) for overall survival in women aged 70 years or younger with advanced-stage epithelial ovarian cancer (EOC), according to a recent study published in JAMA Oncology.

-----

Related Content

Read More

Subscribe to Ovarian Cancer